INHIBIKASE THERAPEUTICS INC - COM (IKT)

CUSIP: 45719W106

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / COM
Total 13F shares
4,288,895
Share change
-382,647
Total reported value
$6,349,000
Price per share
$1.48
Number of holders
24
Value change
-$566,079
Number of buys
9
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 45719W106?
CUSIP 45719W106 identifies IKT - INHIBIKASE THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INHIBIKASE THERAPEUTICS INC - COM (IKT) as of Q1 2022

As of 31 Mar 2022, INHIBIKASE THERAPEUTICS INC - COM (IKT) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 4,288,895 shares. The largest 10 holders included ACT CAPITAL MANAGEMENT, LLC, Kepos Capital LP, VANGUARD GROUP INC, FMR LLC, Antara Capital LP, RENAISSANCE TECHNOLOGIES LLC, HAMILTON LANE ADVISORS LLC, Redmond Asset Management, LLC, Lynwood Capital Management Inc., and Retirement Planning Co of New England, Inc.. This page lists 24 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.